CMP Susquehanna Corp.

  • ID: 1783382
  • May 2006
  • Standard & Poors
1 of 3

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Eight radio station clusters in the top 50 designated market areas in the U.S.; Broadcasting's good margin potential and cash flow generating capabilities; and High radio station asset values. Very high leverage; Management's inexperience operating in the larger markets, where CMP Susquehanna Corp.'s assets are located; Weakness in radio ad demand; and Increased competition from traditional and nontraditional media, limiting cash flow generation and intermediate-term debt reduction. The rating on CMP Susquehanna Corp. reflects its very high leverage, unfavorable secular trends in radio advertising, advertising cyclicality, and the potential for additional acquisitions. These factors are partially offset by CMP's portfolio of large-market radio stations, radio broadcasting's good margin and discretionary cash flow potential, and healthy station asset values. CMP, along...

Companies mentioned in this report are: CMP Susquehanna Radio Holdings Corp.,Cumulus Media Inc.
Action: Review

Note: Product cover images may vary from those shown
2 of 3

CMP Susquehanna Radio Holdings Corp.,Cumulus Media Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.